Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.85
+0.10 (0.31%)
Apr 29, 2026, 1:30 PM CST
5.00%
Market Cap 6.06B
Revenue (ttm) 3.37B
Net Income (ttm) 365.75M
Shares Out 190.20M
EPS (ttm) 1.92
PE Ratio 16.59
Forward PE n/a
Dividend 1.00 (3.15%)
Ex-Dividend Date Jul 11, 2025
Volume 115,190
Average Volume 370,439
Open 31.85
Previous Close 31.75
Day's Range 31.70 - 31.95
52-Week Range 29.62 - 32.60
Beta 0.13
RSI 54.34
Earnings Date May 13, 2026

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1977
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1734
Full Company Profile

Financial Performance

In 2025, Sinphar Pharmaceutical's revenue was 3.37 billion, an increase of 7.00% compared to the previous year's 3.15 billion. Earnings were 365.75 million, an increase of 20.03%.

Financial Statements

News

There is no news available yet.